Home » Stocks » PASG

Passage Bio, Inc. (PASG)

Stock Price: $12.30 USD -0.90 (-6.82%)
Updated Jul 29, 2021 4:00 PM EDT - Market closed
After-hours: $12.05 -0.25 (-2.03%) Jul 29, 4:06 PM
Market Cap 712.50M
Revenue (ttm) n/a
Net Income (ttm) -133.53M
Shares Out 53.98M
EPS (ttm) -2.84
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 29
Last Price $12.30
Previous Close $13.20
Change ($) -0.90
Change (%) -6.82%
Day's Open 13.24
Day's Range 12.26 - 13.43
Day's Volume 263,865
52-Week Range 11.67 - 30.87

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Chief Commercial Officer, Chief Financial Officer and Chief Medical Officer to focus on driving company growth and advancing robust pipeline of transformative therapies for patients with CNS disorders C...

1 week ago - GlobeNewsWire

Passage Bio (NASDAQ: PASG) shares are trading higher after Raymond James initiated coverage on the stock with an Outperform rating and announced a $29 price target. The firm said the company's gene ther...

4 weeks ago - Benzinga

PHILADELPHIA, June 01, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for rare, monogenic central ne...

1 month ago - GlobeNewsWire

PHILADELPHIA, May 11, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for rare monogenic central nerv...

2 months ago - GlobeNewsWire

Focus to be on frontotemporal dementia with granulin mutations Focus to be on frontotemporal dementia with granulin mutations

2 months ago - GlobeNewsWire

PHILADELPHIA, May 05, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for rare, monogenic central ner...

2 months ago - GlobeNewsWire

PHILADELPHIA, April 29, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system d...

3 months ago - GlobeNewsWire

- Krabbe disease, a rare lysosomal storage disorder, has no approved disease-modifying treatment options

3 months ago - GlobeNewsWire

Passage Bio (PASG) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front

3 months ago - Zacks Investment Research

– PBGM01 advancement to clinical development represents key milestone for Passage Bio as a clinical-stage company –

3 months ago - GlobeNewsWire

PHILADELPHIA, March 25, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system d...

4 months ago - GlobeNewsWire

PHILADELPHIA, March 22, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare monogenic central nervous system (C...

4 months ago - GlobeNewsWire

FDA designation will facilitate development and expedited review of company's lead gene therapy product candidates for life-threatening diseases with unmet medical needs: PBGM01 for GM1 gangliosidosis (...

4 months ago - GlobeNewsWire

- On track to initiate three Phase 1/2 clinical programs in the first half of 2021: PBGM01 for GM1 gangliosidosis (GM1), PBFT02 for frontotemporal dementia with granulin mutations, and PBKR03 for Krabbe...

4 months ago - GlobeNewsWire

PHILADELPHIA, March 02, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system d...

4 months ago - GlobeNewsWire

PHILADELPHIA, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system di...

5 months ago - GlobeNewsWire

PHILADELPHIA, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system (C...

5 months ago - GlobeNewsWire

- Phase 1/2 trial expected to commence in first half of 2021

5 months ago - GlobeNewsWire

Passage Bio Inc (NASDAQ: PASG) is leveraging the UPenn Gene Therapy Program to access compelling translational research and develop a range of differentiated adeno-associated virus gene therapies for ra...

5 months ago - Benzinga

– Second Product Candidate Expected to Enter Clinic in First Half of 2021

6 months ago - GlobeNewsWire

A secondary offering will dilute shareholders.

6 months ago - The Motley Fool

PHILADELPHIA, Jan. 21, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare monogenic central nervous system dis...

6 months ago - GlobeNewsWire

PHILADELPHIA, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare monogenic central nervous system dis...

6 months ago - GlobeNewsWire

MENLO PARK, Calif.--(BUSINESS WIRE)--Frazier Healthcare Partners announced the promotion of several members on its Life Sciences team: Aditya Kohli to Venture Partner, Anna Chen to Vice President, and M...

Other stocks mentioned: PHAT
6 months ago - Business Wire

PHILADELPHIA, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system di...

6 months ago - GlobeNewsWire

FDA clearance marks second regulatory authorization for global Phase 1/2 clinical trial, Imagine-1 study,  expected to dose first patient in first quarter 2021

6 months ago - GlobeNewsWire

- Company invests to build in-house capabilities to support advancement of pipeline -

7 months ago - GlobeNewsWire

- MHRA approval represents first clinical trial authorization for the global PBGM01 clinical trial program -

7 months ago - GlobeNewsWire

- Completion of dedicated CGMP suite enhances manufacturing readiness and secures supply chain control to support lead CNS gene therapy product candidates as they advance through clinical trials to comm...

7 months ago - GlobeNewsWire

PHILADELPHIA, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system di...

8 months ago - GlobeNewsWire

Through its unique collaboration agreement, Passage Bio has certain rights to technology highlighted in the University's research, which has the potential to significantly advance nascent field of gene ...

8 months ago - GlobeNewsWire

PHILADELPHIA, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system di...

8 months ago - GlobeNewsWire

Passage Bio, Inc. (PASG) CEO Karl Bruce Goldsmith on Q3 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

– Dosing for first patient in PBGM01 Phase 1/2 trial anticipated in 1Q2021; initial safety and biomarker data expected mid-year 2021 – – Phase 1/2 clinical trials for FTD-GRN and Krabbe expected to init...

8 months ago - GlobeNewsWire

Genetic testing, educational materials and counseling offered at no charge to patients Genetic testing, educational materials and counseling offered at no charge to patients

8 months ago - GlobeNewsWire

PHILADELPHIA, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system di...

8 months ago - GlobeNewsWire

PHILADELPHIA, Oct. 28, 2020 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system di...

9 months ago - GlobeNewsWire

PHILADELPHIA, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system di...

9 months ago - GlobeNewsWire

Passage Bio (PASG) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

9 months ago - Zacks Investment Research

About PASG

Passage Bio, Inc., a genetic medicines company, develops transformative therapies for rare monogenic central nervous system (CNS) diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase (ß-gal) for infantile GM1; PBFT02, which utilizes an AAV1 capsid to deliver to the brain a functional granulin, or GRN, gene encoding progranulin, or PGRN, for the treatment of FTD-GRN; and PBKR03, which utilizes a proprietary, AAV... [Read more...]

Industry
Biotechnology
IPO Date
Feb 28, 2020
Stock Exchange
NASDAQ
Ticker Symbol
PASG
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 7 analysts, the average rating for Passage Bio stock is "Strong Buy." The 12-month stock price forecast is 29.71, which is an increase of 141.54% from the latest price.

Price Target
$29.71
(141.54% upside)
Analyst Consensus: Strong Buy